Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Senior VP and General Counsel Harry Leonhardt Steps Down

NEW YORK, Dec 22 - Nanogen said Friday that Harry Leonhardt has resigned as the company’s senior vice president, general counsel and secretary. Vera Pardee has been appointed vice president, assistant general counsel and secretary, the company said.  

Leonhardt’s resignation comes in the thick of the company’s ongoing patent infringement lawsuit against Motorola and a recent lawsuit against CombiMatrix. Both complaints are related to patents covering electronic microarray technology.

Leonhardt will continue to consult Nanogen on a variety of subjects, the company said, although the extent of his involvement in the ongoing litigation was not immediately clear.

A spokesman from the company could not be reached for comment.

Pardee has been a member of the Nanogen legal department since August 2000. Previously, she was a shareholder at the San Diego law firm of Seltzer Caplan Vitek McMahon, an associate at that firm from 1988 through 1993, and an associate at the Los Angeles office of O'Melveny & Myers from 1983 through 1986.

Howard Birndorf, chairman of the board and CEO of Nanogen, said in a statement that Pardee “has been leading our legal department's efforts to assist in the company's commercial expansion, maintain the growth of our intellectual property portfolio and manage the company's litigation matters, including that against Motorola Inc. and Combimatrix. She has been a valuable asset to Nanogen during this period, and we have welcomed her experience, talents and contributions to the Nanogen team."

Leonhardt remarked, “Nanogen has made substantial progress over the last five years, and I am pleased to have played a role in its growth and development. I look forward to continuing my association with the company as a consultant."


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.